ILAE-Europe

2023 Course Applications
European Chapter Executives are invited to submit applications for funding of courses/symposia sponsored by ILAE-Europe during 2023.
Letter to European Chapters - Call for 2023 Course Applications
ILAE Endorsement Procedure | ILAE Curriculum Learning Objectives
Application for ILAE Endorsement & Funding | Deadline: 20 January 2023
EpiCARE

EpiCARE -- a European Reference Network for Rare and Complex Epilepsies -- connects 28 expert centres in 13 Eruopean countries with the aim of aiding the diagnosis and treatment of rare epilepsy patients by using e-tools and cross-country e-consultance. EU member states without EpiCARE centres can nominate affiliated partners to join the network.
Monthly EpiCARE Webinars: Free monthly webinars with topics related to rare and complex epilepsies and research
EpiCARE Designation of affiliated partners
Award Winners Announced
ILAE-Europe is pleased to announce the recipients of the European Awards 2018. The awards were presented during the Welcome Ceremony of the 13th ECE on Sunday 26th August.

European Epileptology Award - Emilio Perucca (Italy)
European Young Investigator Award - Birgit Frauscher (Austria/Canada)
European Young Investigator Award - Sylvain Rheims (France)
European Epilepsy Education Award - Kristina Malmgren (Sweden)
Latest News

About ILAE
International Epilepsy Day 2023 in Greece
For International Epilepsy Day 2023, the Greek League Against Epilepsy and the Greek National Association Against Epilepsy joined forces with 19 municipalities and institutions throughout Greece to light up local monuments and central buildings in purple as a way of raising awareness of epilepsy.
10 March, 2023

World News
Survey on epilepsy stereo-electroencephalography (SEEG) surgery terminology
The purpose of this survey is to assess the various opinions regarding the SEEG terminology and surgery outcome scores from the clinical community across the globe, and establish a reasonable consensus.
7 March, 2023

Clinical Research
Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy
Memantine is an N-methyl-D-aspartate receptor antagonist, approved for dementia treatment. There is limited evidence of memantine showing benefit for paediatric neurodevelopmental phenotypes, but no randomized placebo-controlled trials in children with developmental and epileptic encephalopathy.
6 March, 2023

About ILAE
ILAE-IBE Joint Statement on International Epilepsy Day 2023
Today, on International Epilepsy Day, the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) are calling for greater understanding and intersectoral action to tackle the stigma and discrimination faced by people with epilepsy worldwide.
13 February, 2023

World News
Improving the lives of people with epilepsy
Epilepsy is one of the most common neurological disorders globally. The WHO epilepsy technical brief aims to strengthen action for epilepsy and complements the Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031.
12 December, 2022
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community